JP6295205B2 - 心血管疾患のリスクを低減する方法 - Google Patents

心血管疾患のリスクを低減する方法 Download PDF

Info

Publication number
JP6295205B2
JP6295205B2 JP2014551345A JP2014551345A JP6295205B2 JP 6295205 B2 JP6295205 B2 JP 6295205B2 JP 2014551345 A JP2014551345 A JP 2014551345A JP 2014551345 A JP2014551345 A JP 2014551345A JP 6295205 B2 JP6295205 B2 JP 6295205B2
Authority
JP
Japan
Prior art keywords
patient
ldl
compound
pharmaceutical composition
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014551345A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015503588A (ja
JP2015503588A5 (enExample
Inventor
チャールズ エル． ビズゲイール
チャールズ エル． ビズゲイール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metavia
Original Assignee
Gemphire Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gemphire Therapeutics LLC filed Critical Gemphire Therapeutics LLC
Publication of JP2015503588A publication Critical patent/JP2015503588A/ja
Publication of JP2015503588A5 publication Critical patent/JP2015503588A5/ja
Application granted granted Critical
Publication of JP6295205B2 publication Critical patent/JP6295205B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2014551345A 2012-01-06 2013-01-04 心血管疾患のリスクを低減する方法 Active JP6295205B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261584002P 2012-01-06 2012-01-06
US61/584,002 2012-01-06
PCT/US2013/020317 WO2013103842A1 (en) 2012-01-06 2013-01-04 Methods of reducing risk of cardiovascular disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018026939A Division JP2018104452A (ja) 2012-01-06 2018-02-19 心血管疾患のリスクを低減する方法

Publications (3)

Publication Number Publication Date
JP2015503588A JP2015503588A (ja) 2015-02-02
JP2015503588A5 JP2015503588A5 (enExample) 2016-02-18
JP6295205B2 true JP6295205B2 (ja) 2018-03-14

Family

ID=48745439

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014551345A Active JP6295205B2 (ja) 2012-01-06 2013-01-04 心血管疾患のリスクを低減する方法
JP2018026939A Pending JP2018104452A (ja) 2012-01-06 2018-02-19 心血管疾患のリスクを低減する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018026939A Pending JP2018104452A (ja) 2012-01-06 2018-02-19 心血管疾患のリスクを低減する方法

Country Status (9)

Country Link
US (2) US10028926B2 (enExample)
EP (2) EP3735967A1 (enExample)
JP (2) JP6295205B2 (enExample)
CN (2) CN110025608A (enExample)
AU (1) AU2013207423B2 (enExample)
CA (1) CA2861643C (enExample)
HK (1) HK1201452A1 (enExample)
MX (1) MX367352B (enExample)
WO (1) WO2013103842A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DK4108671T3 (da) 2010-10-01 2025-01-06 Modernatx Inc Modificerede nukleosider, nukleotider og nukleinsyrer samt anvendelser deraf
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
JP6113737B2 (ja) 2011-10-03 2017-04-12 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
US9440754B2 (en) 2012-03-29 2016-09-13 R.P. Scherer Technologies, Llc Three circuit fill system for blow fill seal containers
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
EP2834259A4 (en) 2012-04-02 2016-08-24 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
BR112015026513A2 (pt) 2013-04-17 2017-07-25 Pfizer derivados de n-piperidin-3-ilbenzamida para tratar as doenças cardiovasculares
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
AU2015346037A1 (en) 2014-11-14 2017-07-06 Gemphire Therapeutics Inc. Processes and intermediates for preparing alpha,omega-dicarboxylic acid-terminated dialkane ethers
WO2016149191A1 (en) 2015-03-13 2016-09-22 Esperion Therapeutics, Inc. Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
MA41793A (fr) * 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
RU2018120599A (ru) * 2015-11-06 2019-12-09 Джемфир Терапьютикс, Инк. Лечение смешанной дислипидемии
AU2017224230A1 (en) * 2016-02-26 2018-08-30 Gemphire Therapeutics Inc. Treatment of patients with homozygous familial hypercholesterolemia on lipid lowering therapy
US20210361618A1 (en) * 2017-02-08 2021-11-25 Esperion Therapeutics, Inc. Triplet combination formulations and methods for treating or reducing the risk of cardiovascular disease
IL269884B2 (en) 2017-04-18 2023-09-01 Gemphire Therapeutics Inc Gamkaban its accepted pharmaceutical salts, their compositions and methods of their use
US20190008779A1 (en) * 2017-05-11 2019-01-10 Gemphire Therapeutics Inc. Gemcabene compositions and methods of use thereof
CN109666727B (zh) * 2018-12-29 2020-11-06 中国药科大学 一种高活性抑制pcsk9表达的微小rna的用途
RS66416B1 (sr) 2019-01-18 2025-02-28 Astrazeneca Ab 6'-[[(1s,3s)-3-[[5-(difluorometoksi)-2-pirimidinil]amino]ciklopentil]amino][1(2h),3'-bipiridin]-2-on kao inhibitor pcsk9 i metode njegove primene
US12344578B2 (en) 2019-06-21 2025-07-01 Esperion Therapeutics, Inc. Salt forms of bempedoic acid and methods for using the same
CN113134086B (zh) * 2020-01-20 2024-05-24 深圳市长卿医学研究院 一种降血脂的药物组合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648387A (en) 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
NZ503982A (en) 1997-12-12 2002-03-28 Warner Lambert Co Statin-carboxyalkylether combinations useful for treating vascular disorders and diabetes mellitus
US6861555B2 (en) 2000-01-25 2005-03-01 Warner-Lambert Company Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith
US20020103252A1 (en) 1997-12-12 2002-08-01 Bisgaier Charles Larry Statin-carboxyalkylether combinations
MXPA01009893A (es) 1999-04-01 2003-07-28 Esperion Therapeutics Inc Compuestos con eter, composiciones y usos de estos.
MXPA03003021A (es) 2000-10-11 2003-07-14 Esperion Therapeutics Inc Compuestos de eter y composiciones para el control del colesterol y usos relacionados.
US6645170B2 (en) 2001-03-05 2003-11-11 Bioject Medical Technologies, Inc. Simplified disposable needle-free injection apparatus and method
US20040229954A1 (en) 2003-05-16 2004-11-18 Macdougall Diane Elaine Selective manipulation of triglyceride, HDL and LDL parameters with 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt
US7345190B2 (en) 2003-11-12 2008-03-18 Ssv Therapeutics, Inc. Carnitine conjugates as dual prodrugs and uses thereof
US7579504B2 (en) 2005-12-07 2009-08-25 Gilead Sciences, Inc. ABCA1 elevating compounds
CN101522623B (zh) * 2006-08-03 2013-06-12 塔夫茨大学信托人 无潮红烟酸类似物和其使用方法

Also Published As

Publication number Publication date
CN110025608A (zh) 2019-07-19
AU2013207423A1 (en) 2014-07-24
US20150005386A1 (en) 2015-01-01
EP2800564A1 (en) 2014-11-12
HK1201452A1 (en) 2015-09-04
EP2800564A4 (en) 2015-07-22
US10709678B2 (en) 2020-07-14
US20180303779A1 (en) 2018-10-25
WO2013103842A1 (en) 2013-07-11
CA2861643A1 (en) 2013-07-11
EP3735967A1 (en) 2020-11-11
US10028926B2 (en) 2018-07-24
CA2861643C (en) 2020-10-06
CN104136023A (zh) 2014-11-05
AU2013207423B2 (en) 2017-10-12
MX367352B (es) 2019-08-16
JP2018104452A (ja) 2018-07-05
JP2015503588A (ja) 2015-02-02
EP2800564B1 (en) 2020-05-06
MX2014008180A (es) 2014-10-14

Similar Documents

Publication Publication Date Title
JP6295205B2 (ja) 心血管疾患のリスクを低減する方法
Nikolic et al. ETC-1002: a future option for lipid disorders?
JP6940411B2 (ja) Ｅｔｃ１００２及びエゼチミブを含む固定用量組合せ物及び製剤並びに心血管疾患を処置するか又は心血管疾患のリスクを低減させる方法
CN114159564A (zh) 包含etc1002及他汀类药物的固定剂量组合
JP2009540003A (ja) Ａａ１ｒａの低頻度投与を含む腎機能の長期間にわたる改善
Atar et al. Do we need new lipid-lowering agents in the era of PCSK9 inhibitors? Recent advances
Tardif et al. High-density lipoprotein/apolipoprotein AI infusion therapy
JP6207560B2 (ja) 膵炎を治療するためのゲムカベンおよび誘導体
HK40007806A (en) Methods of reducing risk of cardiovascular disease
Derosa et al. Prospects for the development of novel anti-hyperlipidemic drugs
AU2015202580B2 (en) Gemcabene and derivatives for treating pancreatitis
Shabana et al. Novel Agents for Treatment of Hyperlipidemia
Saleem et al. High-density lipoproteins: a novel therapeutic target for cardiovascular disease
Genest 75 Secondary prevention strategies post myocardial infarction
Pitsavos Beyond LDL Cholesterol: The role of LDL particles and HDL
Patel et al. Lipid-Modifying Therapy
Davidson 505 COMBINATION THERAPY WITH STATINS AND OMEGA 3 FATTY ACIDS
Ganda Lipid management in the metabolic syndrome

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20150327

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160920

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170317

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170815

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180105

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180123

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180219

R150 Certificate of patent or registration of utility model

Ref document number: 6295205

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250